The health innovations of 2024 are not just a series of futuristic gadgets. Behind each advancement, there is a tightening regulatory framework, unresolved personal data issues, and tools whose real effectiveness still needs to be proven in everyday conditions. Here are the concrete changes reshaping the medical landscape this year.
European Regulation of Medical AI: What the AI Act Changes for Patients
Have you ever used an app that analyzes a mole or provides a pre-diagnosis based on your symptoms? These tools rely on artificial intelligence. Until recently, their market entry was not governed by any specific text in Europe.
The regulation (EU) 2024/1689, published in the Official Journal of the European Union on July 12, 2024, changes the game. Known as the AI Act, it classifies certain AI systems used in medicine as high-risk systems. In practice, this means that publishers must comply with specific requirements: documented risk management, quality of training datasets, traceability of algorithmic decisions, and mandatory human oversight.
For a patient, the direct consequence is better transparency. Software that helps a radiologist spot an anomaly on a scan will need to explain, at least partially, on what criteria it bases its suggestion. The doctor remains the decision-maker, but they have a regulatory safety net that American or Asian competitors do not yet impose at this level of detail.
Following the news on Zone Santé helps to understand how these obligations translate month after month into French clinical practice.
European Health Data Space: Interoperability and Sovereignty
Imagine you are consulting a specialist in another EU country. Today, transmitting your medical record often remains an obstacle course: incompatible formats, missing authorizations, administrative delays.
The European Health Data Space (EHDS) aims to solve this problem. After a political agreement reached in 2024 between the European Council and Parliament, the regulation was definitively adopted in early 2025. It organizes two complementary uses:
- Primary access: every European citizen will be able to consult and share their health data (prescriptions, test results, reports) beyond national borders.
- Secondary access: researchers, health innovation companies, and public authorities will be able to reuse this anonymized data to advance research or guide prevention policies.
- Governance: national bodies responsible for data access must ensure privacy compliance and arbitrate usage requests.
The debate is no longer about the digitization of care, which is already well underway, but about who controls the data and under what conditions. For French healthtech companies, this is both an opportunity (a harmonized data market) and a constraint (strict compliance rules).
Social Robots and Real-World Evaluation
Surgical robots occupy a lot of media space. There is less talk about social robots, machines designed to interact with patients in nursing homes, rehabilitation, or psychiatry.
The assessment of these devices is nuanced. They can reduce the isolation of some elderly people or facilitate cognitive stimulation exercises. However, their clinical effectiveness has not yet been demonstrated by large-scale studies.
Real-world evaluation must precede any widespread deployment. In other words, just because a robot works in a laboratory or in a pilot hospital does not mean it will deliver the same benefits everywhere. The conditions of oversight, staff training, and acceptance by residents are as important as the technology itself.
Health Innovations in France: Funding and Digital Sovereignty
The French digital health market faces a paradox. French companies are developing recognized solutions (remote monitoring, care coordination platforms, connected medical devices), but their access to funding remains more complex than that of their American counterparts.
Why this gap? Several factors combine:
- Regulatory validation cycles are long, delaying market entry and thus return on investment for funds.
- Reimbursement by Health Insurance conditions large-scale adoption: without coverage, even a high-performing device struggles to spread.
- The issue of data sovereignty pushes public authorities to favor hosting on European soil, adding infrastructure costs.
These constraints do not stifle innovation, but they shape its development. French companies that succeed are those that integrate regulatory compliance from the design stage, rather than treating it as a final step. This reflex, still minority a few years ago, is becoming a competitive advantage within the framework of the AI Act and the EHDS.
The year 2024 marks less of a technological break than a regulatory turning point. The tools exist, some for several years. What is changing is the framework in which they must prove their value: algorithmic transparency, data interoperability, rigorous clinical evaluation. For patients as well as healthcare professionals, these requirements are a much more concrete protection than a promise of innovation.
